Mutated IDH1/2 can be functionally considered as highly specific tumor-associated neoantigens that could be targeted by immunotherapy; a vaccine targeting mutant IDH1 showed antitumor activity in a glioma animal model opening the possibility of new experimental therapies (48). Here, IDH1 is linked to neoplasm.